ORIC Pharmaceuticals Touts Positive Efficacy, Safety Data From Early-Stage Prostate Cancer Candidate, Raises Capital

ORIC Pharmaceuticals (ORIC) announced positive preliminary Phase 1b trial data for ORIC-944 in combination with androgen receptor inhibitors in metastatic castration-resistant prostate cancer (mCRPC) patients, showing a 59% PSA50 response rate, with 47% confirmed after one month, and a 24% PSA90 response rate; the treatment was generally well-tolerated. Concurrently, ORIC raised $125 million in a private placement, extending its cash runway into the second half of 2027, and the stock price subsequently rose 24.7% in premarket trading.

Analysis

ORIC Pharmaceuticals Inc. (ORIC) has presented encouraging preliminary efficacy and safety data from its ongoing Phase 1b trial of ORIC-944 in combination with androgen receptor (AR) inhibitors for metastatic castration-resistant prostate cancer (mCRPC). The data revealed that 59% of patients (10/17) achieved a PSA50 response, with a confirmed PSA50 response rate of 47% (8/17) after one month, and an additional PSA response is pending confirmation. Notably, 24% of patients (4/17) achieved a confirmed PSA90 response, with these responses observed across all ORIC-944 dose levels and when combined with either apalutamide or darolutamide. The safety profile appears favorable, with ORIC-944 in combination being generally well tolerated and most adverse events (AEs) classified as Grade 1 or 2, consistent with PRC2 and AR inhibition. ORIC plans to complete the dose exploration phase by mid-2025, proceed to dose optimization in the second half of 2025, and initiate a global Phase 3 registrational trial in the first half of 2026. Concurrently, the company has strengthened its financial position by raising $125 million through a private placement, selling approximately 19.2 million shares at $6.50 per share. This financing extends its cash runway into the second half of 2027, designed to fund operations through the anticipated primary endpoint readout from the first ORIC-944 Phase 3 trial. The market reacted positively to these developments, with ORIC's stock price increasing by 24.7% to $7.44 in premarket trading.

Key Decisions for Investors

• The positive preliminary Phase 1b efficacy and safety data for ORIC-944, combined with the significantly extended cash runway to 2H 2027, materially de-risks the company's near-to-medium term outlook and supports a more favorable valuation.
• Investors should monitor key upcoming catalysts, including the completion of the Phase 1b dose exploration by mid-2025 and subsequent dose optimization data in 2H 2025, which will be crucial in validating the therapeutic potential and informing the pivotal Phase 3 trial design.
• Given the substantial premarket share price appreciation, accumulation strategies should consider the current valuation against the long-term potential contingent on continued clinical success and eventual regulatory approval of ORIC-944.